Stem Cell Therapy for Diabetes and Liver Disease: China's Emerging Clinical Evidence

Metabolic Diseases: A Growing Priority in Chinese Stem Cell Research

Diabetes and liver disease represent massive health burdens in China — the country has the world's largest population of diabetes patients (140 million) and a significant burden of liver cirrhosis from hepatitis B and alcohol-related disease. It is unsurprising that Chinese researchers have invested heavily in stem cell approaches for both conditions.

Type 1 Diabetes: Islet-Directed Approaches

Type 1 diabetes — an autoimmune disease destroying pancreatic beta cells — has two potential stem cell therapeutic targets: replacing lost beta cells (regenerative) and suppressing the autoimmune attack (immunomodulatory).

MSC Therapy for Preserving Beta Cell Function

The strongest published evidence for MSC therapy in T1D comes from a Phase II RCT at Beijing Union Medical College Hospital (n=42, newly diagnosed T1D within 12 months, published in Diabetes Care, 2023):

• Primary endpoint (C-peptide AUC at 12 months): +31% preservation in MSC group vs. -27% decline in control group
• HbA1c: Significantly better maintained in MSC group (7.2% vs. 8.1% at 12 months)
• Insulin dose requirements: 22% lower in MSC group at 12 months
• Safety: No serious adverse events; two mild infusion reactions resolved spontaneously

This represents meaningful preservation of residual beta cell function — clinically important because even partial beta cell preservation is associated with better long-term glycemic control and lower hypoglycemia risk.

ESC/iPSC-Derived Beta Cell Replacement

The more ambitious approach — replacing destroyed beta cells entirely using stem cell-derived islet cells — is at an early clinical stage in China. Phase I trials at Peking University and Zhejiang University are underway, building on the global work pioneered by ViaCyte (now Vertex) in the US. No efficacy data is yet published from Chinese sites.

Type 2 Diabetes: Targeting Complications and Insulin Resistance

For T2D, the stem cell research focus is primarily on managing complications rather than replacing insulin production. Key areas:

Diabetic Nephropathy

Renal MSC infusion trials targeting diabetic nephropathy (a leading cause of kidney failure in China) have reported:

• Reduction in urine albumin-to-creatinine ratio (UACR) at 6 months: -34% in MSC group vs. -8% in standard-of-care control (Phase II, n=30, Ruijin Hospital Shanghai, 2024)
• eGFR stabilization in 70% of treated patients vs. continued decline in control group
• Safety profile acceptable; no acute kidney injury events

Diabetic Peripheral Neuropathy

Small trials of intramuscular MSC injection in the lower limbs for diabetic neuropathy and peripheral vascular disease report improvements in ankle-brachial index and nerve conduction velocity in early-phase studies — results requiring confirmation in larger trials.

Liver Cirrhosis: Significant Trial Activity

Liver cirrhosis — characterized by irreversible scarring replacing functional hepatic tissue — is an area of substantial Chinese stem cell trial activity. The rationale: MSCs have anti-fibrotic properties and can support hepatocyte regeneration through paracrine mechanisms.

Published Clinical Evidence

A 2023 meta-analysis in Hepatology (primarily analyzing Chinese RCT data, combined n=632) assessed MSC infusion in decompensated liver cirrhosis:

• Model for End-Stage Liver Disease (MELD) score improvement at 6 months: Mean reduction of 2.8 points in MSC group vs. 0.4 points in control
• Serum albumin improvement: Statistically significant (p=0.003)
• Child-Pugh score improvement: 45% of MSC-treated patients vs. 22% controls showed ≥1 class improvement
• 12-month survival: 88% vs. 72% in control group (though this endpoint requires cautious interpretation given heterogeneous patient populations across included trials)

The most rigorous single trial comes from PLA General Hospital (Beijing) — a multicenter RCT (n=110) showing 28-week MELD score improvement with a statistically significant treatment effect. Notably, benefits were stronger in hepatitis B-related cirrhosis than alcohol-related cirrhosis.

Important Limitations

Metabolic stem cell trials face specific methodological challenges:

• Liver cirrhosis trials often have short follow-up periods — whether structural fibrosis reversal occurs is not established
• Many diabetes trials enroll newly diagnosed patients whose outcomes may reflect the natural honeymoon phase of disease
• Blinding is difficult in cell therapy trials, increasing risk of performance bias

Despite these limitations, the metabolic disease trial data is among the more clinically promising outside of hematological and autoimmune indications.

Sources: Diabetes Care 2023 (PMID: 37086393); Hepatology 2023 meta-analysis; Ruijin Hospital nephropathy trial, Journal of Diabetes Research 2024; Stem Cell Research & Therapy 2024.